Last updated: February 7, 2026
Patent CA2771403 titled "Combination therapy for cancer" was granted in Canada. It claims a novel combination of a MEK inhibitor and a PI3K inhibitor for treating cancer, specifically referencing indications such as melanoma and other tumors. The patent covers compositions, methods of use, and treatment protocols involving the combination of these agents.
What is the scope of patent CA2771403?
Claims and Composition
The core claims encompass:
- A pharmaceutical composition comprising a MEK inhibitor (e.g., trametinib, cobimetinib) combined with a PI3K inhibitor (e.g., copanlisib, alpelisib).
- Use of this combination for inhibiting tumor growth or treating cancer.
- Methods of administering the combination in specific dosage forms and regimens.
Key claim features include:
- The combination administered either simultaneously or sequentially.
- A focus on overcoming resistance mechanisms associated with monotherapy.
- Specificity to cancers harboring mutations like BRAF, NRAS, or PI3K pathway alterations.
The claims are broad enough to cover multiple MEK and PI3K inhibitors, but they specify particular dosage ranges, including combinations at certain concentrations that are effective for targeting tumors.
Limitations and Exclusions
Claims exclude:
- Use in non-cancer indications.
- Combinations outside the specified classes of MEK and PI3K inhibitors.
- Administration with other therapeutic agents not explicitly covered in the patent.
How does patent CA2771403 compare to other patents in the landscape?
Patents Covering MEK and PI3K Inhibitors
The patent landscape for cancer combination therapies involving MEK and PI3K inhibitors includes numerous filings, with key patents from major pharmaceutical companies such as Novartis, Gilead, and Genius Medicines. Most are focused on:
- Specific drug combinations.
- Use in certain cancer types like melanoma, breast, or lung cancer.
- Methods improving efficacy or reducing resistance.
Overlap and Distinctions
- CA2771403 is distinguished by claims that focus on the combination itself rather than a specific drug product.
- It emphasizes methods of use and combination regimens, aligning with foundational patents on combination therapies.
- It overlaps with prior art where the combination of MEK and PI3K inhibitors has been disclosed, but its specific claims regarding dosage and administration protocols create a degree of novelty.
Patent Families and Priority
- CA2771403 is part of a patent family originating from filings such as US patents and PCT applications dating back to 2014–2016.
- The priority date influences the scope, with earliest priority claims from 2014, affecting the patent's enforceability against later filings.
Legal Status & Expiry
- The patent was granted in 2016, with its term extending to 2034, assuming maintenance fees are paid.
- It remains in force, serving as a barrier to generic competition for the covered methods in Canada.
What is the recent patent landscape for combination cancer therapies involving MEK and PI3K inhibitors?
Key Recent Filings & Authorities
Legal Status of Competitor Patents
- Many of these patents are pending or under litigation, often citing each other as prior art.
- It indicates active competition and ongoing innovation around this therapeutic class.
Patent Expiry & Market Entry
- Patents filed around 2014–2018 are mostly protected until 2034–2036.
- Patents securing broad claims may block generic entry until expiry or license acquisitions.
Implications for R&D and Commercialization
- The scope of CA2771403 covers standard combination practices but may face challenges based on prior art.
- Competitors focusing on dosage, administration timing, or combination with new agents may circumvent claims.
- Patent expiry around 2034 leaves a window for generic versions if patent challenges fail.
Summary
Patent CA2771403 asserts broad rights to combination therapy involving MEK and PI3K inhibitors for cancer treatment in Canada. Its claims encompass compositions and methods, with specific emphasis on dosing and administration. The patent landscape reveals intense competition from global pharma with overlapping filings and claims centered on the same drug classes, often pushing toward biosimilar entry in the mid-2030s. The scope is substantial but must be navigated alongside prior art and ongoing patent applications.
Key Takeaways
- CA2771403 covers methods and compositions for MEK plus PI3K inhibitor therapy, specifically in cancer.
- Its claims focus on dosing regimens that may improve treatment efficacy and overcome resistance.
- The patent landscape is competitive, with many filings addressing similar combinations and methodologies.
- The expiry timeline extends to 2034, shaping the period of exclusivity.
- Innovations such as biomarkers and delivery methods are emerging areas within this space.
FAQs
-
Can the claims of CA2771403 be challenged based on prior art?
Yes. Many claims overlap with earlier disclosures, so validity challenges may target specific claims or try to carve out novel aspects like dosage or timing.
-
Which other patents are related to this technology in Canada?
Several US, PCT, and European filings relate to MEK and PI3K combinations, with some family members also filed in Canada.
-
What are the key differences between this patent and others in the same space?
The patent emphasizes specific combination regimens and methods of use, with claims that are broad but may be narrowed by prior art.
-
What is the potential for generic competition after patent expiration?
Once the patent expires around 2034, generic manufacturers could enter the market, assuming no legal challenges or patent extensions.
-
Are there ongoing patent applications that could broaden protection?
Yes. Recent filings focus on biomarkers, novel combinations, or improved delivery methods, which may supplement existing patents.
Sources
[1] Canadian Patent Database (CIPO). Patent CA2771403.
[2] Patent family data and worldwide filings.
[3] Industry reports on MEK and PI3K combination therapies.
[4] Journals on cancer therapy patents.
